Ueno M, Takeda H, Takai A, Morimura H, et al. CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study. J Gastroenterol 2024 Sep 18. doi: 10.1007/s00535-024-02150.
PMID: 39289234